BIOA · BioAge Labs, Inc.
Market Cap
$436.02M
Shares
45.90M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$9.50
Open$9.61
Day$9.20–9.63
52W close$4.65–25.10
Avg vol 30d1.1M
Short int2.2M · 4.8% float · 1.9d
Short vol44%
Last earningsAug 5, 2026
DataSep 2024–Aug 2026
Filing10-Q · Aug 5
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−44%
below
Price vs 50-day avg
−46%
below
RSI (14)
33
neutral
MACD trend
Positive
52-week position
24%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−12%
trailing
6-month return
−55%
trailing
YTD return
−28%
this year
Relative strength
−68%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $17 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +27 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.83% of float · ▼ -13.6% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
151 holders — near 2-yr high, broad support
Squeeze score
42
elevated · 0–100
Fundamentals
EPS growth
+66%
Y/Y
Free cash flow
$-82.3M
Balance sheet
$345.8M
net cash
Quant / Vol
risk profile
Volatility
109%
annualized · 1-yr
Max drawdown
−64%
past year
ATR
11.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−44%
Bearish
Price vs 50-day avg
−46%
Bearish
RSI (14)
33
Neutral
MACD trend
Positive
Bullish
52-week position
24%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $17 › 200d $17 — 50d above 200d
Institutional flow
Accumulating
+3% holders QoQ · +27 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.83% of float · ▼ -13.6% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
151 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $10 · 24%
Range high $25
vs 200-day avg -44%
vs 50-day avg -46%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BIOA
this stock
BioAge Labs, Inc.
|
$436.02M | -28.2% | — | — | 4.8% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.58B | +15.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$47.69B | -0.1% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.46B | -0.8% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BIOA | +1.3% | -11.9% | -54.7% | +5.1% | -28.2% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | +0.8% | -13.1% | -68.0% | +2.4% | -40.7% |
Key facts
CIK
1709941
CUSIP
09077V100
13F (30d)
134 filings
131 filers
Visit website
Investor relations